FREDERICK, Md., March 15, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices announced today that the OTC Bulletin, the leading global trade publication for over-the-counter healthcare products, has chosen its ActiPatch® Musculoskeletal Chronic Pain Relief Therapy as the winner for the "Best OTC Marketing Campaign on a Small Budget" award.
A panel of six independent over-the-counter marketing experts evaluated the seven nominees from some of the world's leading pharmaceutical companies. While making its commendation the award judges said, "Faced with getting the maximum impact from an annual marketing budget of less than £0.5 million, BioElectronics rose to the challenge to support its ActiPatch Pain Relief Therapy medical device. I particularly like ActiPatch's sensible approach to trial pricing through the 'Try & Tell' mechanism, knowing that there was a strong repeat rate after trial. This programme enabled a strong consumer insight on efficacy to be turned into good growth. The seven-day trial patches give consumers the opportunity to feel the benefit of ActiPatch without a large outlay before they have been convinced it works." BioElectronics was top entrant in the category with 43 points to Merck Consumer Health 36.
"We are very pleased that this award illustrates the success of our "Try & Tell" 7-Day Trial marketing program, which helped launch our ActiPatch chronic pain therapy and expand our sales," said Ben Fichter, Marketing Manager. "An added benefit of this marketing campaign is that it allowed us to generate significant amounts of data on these chronic pain sufferers and compile registry data of over 5,000 users which is published in Pain Management medical journal (http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35)."
After using the ActiPatch trial device:
- 65% experience clinically significant chronic pain
- This group reported a 57% reduction in pain
Long term ActiPatch users reported these benefits:
- 2/3 (including opioid users) reported moderate to complete elimination of pain medications.
- 2/3 reported improved sleep,
- 3/4 increased physical activity and
- 4/5 a substantial improvement in overall quality of life.
In summary, BioElectronics innovative marketing campaign has led to extensive trialing of the ActiPatch 7-day trial device expanding the availability of ActiPatch in retail stores, consumer acceptance and increasing sales.
The complete details on the award winners are available in the 2016 OTC Awards Supplement http://www.otc-bulletin.com/media/34911/otc-winners-supplement2016.pdf
About BioElectronics Corporation
BioElectronics Corporation (www.bielcorp.com) is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses.
SOURCE BioElectronics Corporation